👥 Consenso de los KOLs en #ESMO26 ¿quién apoya cada ensayo?
Con ACUVOX y @OncoAlert monitorizamos la postura de los líderes de opinión frente a cada readout:
✅ Consenso positivo absoluto: VOLGA (7 vs 0), DeLLphi-305 (5 vs 0) y DASL-HiCaP (3 vs 0).
⚠️ Debate abierto / Críticas: KEYNOTE-866 y KEYNOTE-B49 generan discrepancias notables entre los expertos.
Descubre el mapa de opiniones completas 👉 https://f.mtr.cool/7xqd9gpy4q
#ESMO26 #ACUVOX #OncoAlert #CongressIntelligence
22 views · 1 like · 1 repost · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgPerioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgSource: Oncobites.tv · x.com